Ongoing treatment(s)-Hormonal therapy - Page 2 of 11 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Hormonal therapy Posts on Medivizor

Evaluating the impact on quality of life of giving enzulatumide in combination with hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the impact on quality of life of giving enzulatumide in combination with hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

Posted by on Dec 6, 2020 in Prostate cancer | 0 comments

In a nutshell This study investigated the quality of life after treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) with enzalutamide (Xtandi) in combination with hormone therapy. The study found that enzalutamide + hormone therapy improved the quality of life of patients, compared to hormone therapy...

Read More

Predicting response to 10 years of endocrine therapy in patients with hormone receptor positive early stage breast cancer

Predicting response to 10 years of endocrine therapy in patients with hormone receptor positive early stage breast cancer

Posted by on Nov 15, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated whether Breast Cancer Index (BCI) can predict benefits from extended endocrine therapy (EET) in patients with hormone-receptor-positive (HR+) early-stage breast cancer (BC). The authors found that BCI can predict which patients would benefit from 10 years of EET. Some background Endocrine therapy (ET) prevents tumor...

Read More

Evaluating the effects of chemotherapy on cognitive function in patients with early breast cancer

Evaluating the effects of chemotherapy on cognitive function in patients with early breast cancer

Posted by on Jun 28, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated the contribution of chemotherapy on cancer-related cognitive impairment (CRCI) reported by women with early breast cancer. The authors found that chemotherapy added to hormonal therapy caused early and short-term CRCI in such patients, compared to hormonal therapy alone. Some background CRCI refers to problems in...

Read More

Does enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?

Does enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?

Posted by on Jun 21, 2020 in Prostate cancer | 0 comments

In a nutshell The study assessed whether enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) increased overall survival (OS) of patients with nonmetastatic, castration-resistant prostate cancer (CRPC). The study found improved survival in patients with CRPC treated with enzalutamide. Some background ADT is a type of hormonal therapy...

Read More

The use of relugolix in addition to radiotherapy in patients with prostate cancer

Posted by on May 2, 2020 in Prostate cancer | 0 comments

In a nutshell The study investigated the use of relugolix (Relumina), a hormonal therapy drug, in addition to radiotherapy (RT), in managing prostate cancer. The study found that relugolix was effective in reducing androgen (male sex hormones such as testosterone) levels and well tolerated in these patients. Some background Prostate...

Read More

Looking for patients with breast cancer on hormonal therapy to trial a new drug for vasomotor symptoms

Posted by on Jun 29, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the effectiveness of Q-122, an experimental drug to treat hot flashes in breast cancer (BC). The main outcome will be the hot flash severity score (HFSS). This trial is recruiting in the United States and Australia. The details Breast cancer (BC) is one of the most common cancers in women....

Read More

Abiraterone acetate plus prednisone: an evaluation of the long-term effectiveness in prostate cancer treated with hormonal therapy.

Posted by on May 18, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated if abiraterone acetate (Zytiga) and prednisone (Deltasone) added to androgen deprivation therapy (ADT) improve survival in patients with advanced prostate cancer. They found that this combination was effective at improving survival in these patients. Some background...

Read More

Looking for patients with estrogen receptor-positive breast cancer to test a new treatment combination

Posted by on May 11, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...

Read More

What is the optimal timing of exercise therapy for men taking androgen deprivation therapy?

Posted by on Jan 5, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the timing of exercise therapy in patients with prostate cancer taking androgen deprivation therapy (ADT). This study found that starting exercise at the onset of ADT helps preserve muscle mass and bone density.  Some background Androgen deprivation therapy (ADT) is a treatment option in...

Read More

Long term results discussing radiotherapy and hormone therapy treatments for patients with prostate cancer

Posted by on Dec 16, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate whole pelvic radiotherapy (WPRT) compared to prostate only radiotherapy (PORT) with hormonal therapy (HT) before or after radiation for patients with intermediate- or high-risk prostate cancer. This study found that HT before radiotherapy and WPRT had superior long-term survival without cancer growing or...

Read More